Published in Nat Med on October 01, 2000
Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J Virol (2005) 4.01
Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer (2010) 3.55
Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog (2007) 3.16
Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev (2003) 2.90
Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol (2001) 2.87
BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer (2012) 2.80
Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J Virol (2002) 2.71
Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer (2010) 2.68
KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest (2010) 2.55
DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.41
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J Virol (2002) 2.32
Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol (2001) 2.31
Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J Virol (2002) 2.28
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J Virol (2006) 2.11
Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol (2003) 2.07
EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog (2006) 1.71
Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest. J Virol (2006) 1.68
Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev (2002) 1.67
Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol (2004) 1.64
A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest. J Virol (2010) 1.64
Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci (2001) 1.64
Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol (2006) 1.63
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta. J Virol (2003) 1.62
Mechanisms governing expression of the v-FLIP gene of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 1.56
Lytic but not latent infection by Kaposi's sarcoma-associated herpesvirus requires host CSL protein, the mediator of Notch signaling. Proc Natl Acad Sci U S A (2003) 1.54
Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett (2009) 1.54
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood (2008) 1.52
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A (2004) 1.52
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood (2003) 1.51
Transcripts encoding K12, v-FLIP, v-cyclin, and the microRNA cluster of Kaposi's sarcoma-associated herpesvirus originate from a common promoter. J Virol (2005) 1.50
Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis. PLoS Pathog (2007) 1.48
Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res (2007) 1.47
Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A (2005) 1.45
Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl Acad Sci U S A (2006) 1.43
Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe (2014) 1.42
HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis (2008) 1.42
Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J Virol (2010) 1.42
Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology (2008) 1.41
Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett (2011) 1.41
Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist (2011) 1.40
Viral manipulation of DNA repair and cell cycle checkpoints. DNA Repair (Amst) (2009) 1.37
The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol (2007) 1.36
Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol (2006) 1.36
Internal ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein. J Virol (2001) 1.34
Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. J Virol (2004) 1.34
Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions. J Virol (2006) 1.30
Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6. EMBO J (2005) 1.29
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol (2003) 1.28
The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest (2006) 1.26
Activation of the Kaposi's sarcoma-associated herpesvirus major latency locus by the lytic switch protein RTA (ORF50). J Virol (2005) 1.24
The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters. J Virol (2001) 1.24
Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif. J Virol (2004) 1.21
LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc Natl Acad Sci U S A (2004) 1.20
Kaposi's sarcoma-associated herpesvirus induction of chromosome instability in primary human endothelial cells. Cancer Res (2004) 1.19
A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. J Virol (2007) 1.19
Kaposi's sarcoma-associated herpesvirus RTA promotes degradation of the Hey1 repressor protein through the ubiquitin proteasome pathway. J Virol (2009) 1.15
Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. Virology (2007) 1.14
Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol (2007) 1.14
The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency. Future Microbiol (2011) 1.13
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces expression of the helix-loop-helix protein Id-1 in human endothelial cells. J Virol (2003) 1.11
Kaposi's sarcoma-associated herpesvirus K7 protein targets a ubiquitin-like/ubiquitin-associated domain-containing protein to promote protein degradation. Mol Cell Biol (2004) 1.10
Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis. J Clin Microbiol (2006) 1.10
Determination of Kaposi's sarcoma-associated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding. J Virol (2007) 1.09
Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res (2010) 1.09
The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood (2005) 1.08
KSHV microRNAs mediate cellular transformation and tumorigenesis by redundantly targeting cell growth and survival pathways. PLoS Pathog (2013) 1.08
ORF73 of herpesvirus Saimiri strain C488 tethers the viral genome to metaphase chromosomes and binds to cis-acting DNA sequences in the terminal repeats. J Virol (2003) 1.07
Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas. J Virol (2010) 1.07
Poly(ADP-ribose) polymerase 1 binds to Kaposi's sarcoma-associated herpesvirus (KSHV) terminal repeat sequence and modulates KSHV replication in latency. J Virol (2004) 1.05
The Herpesvirus Saimiri open reading frame 73 gene product interacts with the cellular protein p32. J Virol (2002) 1.05
Proteomic analysis of the Kaposi's sarcoma-associated herpesvirus terminal repeat element binding proteins. J Virol (2006) 1.04
Viruses and apoptosis. Int J Exp Pathol (2001) 1.03
Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div (2009) 1.02
Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers. Antiviral Res (2006) 1.02
The interaction of the gammaherpesvirus 68 orf73 protein with cellular BET proteins affects the activation of cell cycle promoters. J Virol (2009) 1.01
Identification of a novel cellular transcriptional repressor interacting with the latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2003) 1.01
The latency-associated nuclear antigen of rhesus monkey rhadinovirus inhibits viral replication through repression of Orf50/Rta transcriptional activation. J Virol (2005) 1.01
Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen. J Virol (2005) 1.01
Role of Kaposi's sarcoma-associated herpesvirus C-terminal LANA chromosome binding in episome persistence. J Virol (2009) 0.99
KSHV: pathways to tumorigenesis and persistent infection. Adv Virus Res (2014) 0.99
Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen modulates K1 expression through its cis-acting elements within the terminal repeats. J Virol (2006) 0.99
ORF73-null murine gammaherpesvirus 68 reveals roles for mLANA and p53 in virus replication. J Virol (2007) 0.99
Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation. J Virol (2008) 0.98
A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening. J Virol (2012) 0.98
Intracellular activated Notch1 is critical for proliferation of Kaposi's sarcoma-associated herpesvirus-associated B-lymphoma cell lines in vitro. J Virol (2006) 0.98
Tissue specificity of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen (LANA/orf73) promoter in transgenic mice. J Virol (2002) 0.98
The latency-associated nuclear antigen interacts with MeCP2 and nucleosomes through separate domains. J Virol (2009) 0.97
Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi's sarcoma associated with HIV/AIDS. PLoS Pathog (2014) 0.97
Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen. J Biol Chem (2011) 0.97
Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet (1995) 10.63
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science (1996) 6.57
Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS (1991) 4.65
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood (2000) 4.22
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol (2001) 2.87
Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature (1993) 2.86
Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet (1995) 2.74
Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol (2006) 2.65
Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med (1999) 2.63
KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene (1997) 2.57
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50
Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature (1993) 2.45
Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. Arch Intern Med (1996) 2.33
The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol (1997) 2.24
Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst (1998) 2.23
Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology (1999) 2.23
Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS (1997) 2.20
The epidemiology of conjunctival squamous cell carcinoma in Uganda. Br J Cancer (2002) 2.18
Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virol (1999) 2.09
Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer (1999) 1.68
Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol (2005) 1.57
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (1993) 1.56
A statistical model for HIV-1 sequence classification using the subtype analyser (STAR). Bioinformatics (2005) 1.55
An experimental evaluation of a loop versus a reference design for two-channel microarrays. Bioinformatics (2004) 1.54
Manifestations of three HHV-8-related diseases in an HIV-negative patient: immunoblastic variant multicentric Castleman's disease, primary effusion lymphoma, and Kaposi's sarcoma. Am J Hematol (2000) 1.50
A low temperature method of isolating normal human articular chondrocytes. Osteoarthritis Cartilage (2005) 1.47
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS (1992) 1.47
Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer (2004) 1.47
VIDA: a virus database system for the organization of animal virus genome open reading frames. Nucleic Acids Res (2001) 1.43
KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood (2000) 1.39
Estimating reassortment rates in co-circulating Eurasian swine influenza viruses. J Gen Virol (2012) 1.34
Internal ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein. J Virol (2001) 1.34
Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8. J Virol (1999) 1.32
HHV8 and skin cancers in immunosuppressed patients. Lancet (1996) 1.29
Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J (1999) 1.28
Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect Dis (1999) 1.23
Serologic evidence for mother-to-child transmission of Kaposi sarcoma-associated herpesvirus infection. JAMA (1998) 1.22
Kaposi's sarcoma herpesvirus as a new paradigm for virus-induced oncogenesis. Curr Opin Oncol (1998) 1.22
Multicenter comparison of PCR assays for detection of human herpesvirus 8 DNA in semen. J Clin Microbiol (1999) 1.22
Genomewide function conservation and phylogeny in the Herpesviridae. Genome Res (2001) 1.19
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer (2000) 1.13
Increasing probability of mother-to-child transmission of HHV-8 with increasing maternal antibody titer for HHV-8. N Engl J Med (1999) 1.12
Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol (1999) 1.07
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax (2006) 1.04
Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro. J Virol (2013) 1.03
Seroepidemiology and molecular epidemiology of Kaposi's sarcoma-associated herpesvirus among Jewish population groups in Israel. J Natl Cancer Inst (2001) 1.03
A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1. Br J Cancer (2006) 1.00
Kaposi's sarcoma. Coupling herpesvirus to angiogenesis. Nature (1998) 0.97
Human herpesvirus type 8 and Kaposi's sarcoma. J Natl Cancer Inst Monogr (1998) 0.96
Prevalence and distribution of HHV-8 in different subpopulations, with and without HIV infection, in Spain. AIDS (2001) 0.95
Detection of antibodies to human herpesvirus 8 in Italian children: evidence for horizontal transmission. Br J Cancer (2000) 0.94
Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda. Br J Cancer (2003) 0.94
Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. Science (1997) 0.93
Seroprevalence of human herpesvirus 8 and its association with Kaposi sarcoma in Brazil. Sex Transm Dis (2000) 0.90
Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. J Infect Dis (1999) 0.90
Viral cyclins. Rev Med Virol (2000) 0.90
HHV8 and skin cancers in immunosuppressed patients. Lancet (1996) 0.89
The evolutionary dynamics of influenza A virus adaptation to mammalian hosts. Philos Trans R Soc Lond B Biol Sci (2013) 0.88
Characterisation of the anti-apoptotic function of survivin-DeltaEx3 during TNFalpha-mediated cell death. Br J Cancer (2007) 0.87
Kaposi's sarcoma-associated herpesvirus: from cell biology to pathogenesis. IUBMB Life (2000) 0.87
Early peripheral lymph node involvement of human herpesvirus 8-associated, body cavity-based lymphoma in a human immunodeficiency virus-negative patient. Arch Pathol Lab Med (2000) 0.86
Gene expression array profile of human osteosarcoma. Br J Cancer (2003) 0.85
Chondroblastomas but not chondromyxoid fibromas express cytokeratins: an unusual presentation of a chondroblastoma in the metaphyseal cortex of the tibia. Histopathology (2007) 0.85
Illicit viral DNA. Nature (1997) 0.82
Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: disease mechanisms, a diagnostic test and specific treatments. J Clin Pathol (2006) 0.81
Comparison of a maedi-visna virus CA-TM fusion protein ELISA with other assays for detecting sheep infected with North American ovine lentivirus strains. Vet Immunol Immunopathol (1999) 0.81
Endothelial cells and cancer. Handb Exp Pharmacol (2006) 0.81
Occurrence of human herpes virus 8 in Kaposi's sarcoma and other tumours in South Africa. S Afr Med J (1997) 0.80
Is KSHV lytic growth induced by a methylation-sensitive switch? Trends Microbiol (2001) 0.78
Primary pulmonary hypertension in a patient with HIV infection. Acta Cardiol (1998) 0.77
Addressing controversies over Kaposi's sarcoma. J Natl Cancer Inst (2000) 0.76
Congenital dislocation of the hip. SA Nurs J (1974) 0.75
[Fatigue...the shadow of every woman]. SA Nurs J (1966) 0.75
Treatment of good-risk, stage II, non-seminomatous testis cancer. Lancet (1994) 0.75
The isolation and characterisation of plant sequences homologous to human hypervariable minisatellites. EXS (1991) 0.75
Single amino acid substitutions disrupt tetramer formation in the dihydroneopterin aldolase enzyme of Pneumocystis carinii. Biochemistry (1998) 0.75
[Honey]. SA Nurs J (1966) 0.75
[The first drink]. SA Nurs J (1966) 0.75
[Opium and addiction]. SA Nurs J (1965) 0.75
[Migraine]. SA Nurs J (1966) 0.75
[Writing as a hobby]. SA Nurs J (1966) 0.75
Computational inference of replication and transcription activator regulator activity in herpesvirus from gene expression data. IET Syst Biol (2008) 0.75